Gerresheimer's Drastic Restructuring Amid Accounting Crisis
Published on 03/17/2026 at 03:56 | Redaktion boerse-global.de
Facing a severe crisis of confidence following a significant accounting scandal, packaging specialist Gerresheimer is implementing a radical restructuring plan. The company is taking extreme measures to salvage its capital structure, including the divestment of a key subsidiary and the consolidation of its manufacturing footprint. With ongoing investigations by German financial regulator BaFin and delayed financial statements, the pressure on the Düsseldorf-based firm is immense.
Asset Sale and Production Consolidation
In a move to strengthen its balance sheet, Gerresheimer has mandated Morgan Stanley to facilitate the sale of its wholly-owned US subsidiary, Centor, before year-end. Recorded on the books at €292 million as of late 2024, the division specializes in packaging for prescription drugs and is considered highly profitable. While the transaction will provide liquidity, it is expected to materially weaken the group's future earnings power. Concurrently, the company will shutter its Chicago Heights glass plant in the United States by the end of 2026, transferring production to existing facilities in Italy and India.
The Root Cause: A Deepening Scandal
These severe cuts are a direct response to a profound trust crisis. BaFin is currently examining interim reports from the previous year. The focus of the probe is on potentially improper "bill-and-hold" agreements, where revenue appears to have been recognized before the physical delivery of goods. An external special audit is now severely hampering the preparation of the company's regular financial statements.
This uncertainty has triggered immediate consequences in the capital markets. The inability to publish the audited 2025 annual report by the planned deadline of end-March puts Gerresheimer's membership in the SDAX index at risk. An exclusion would force index-tracking funds to sell their holdings, creating additional downward pressure on the share price. The massive uncertainty is already reflected in a precipitous stock decline: the equity has lost 77.5% of its value over a twelve-month period, currently trading at around €18.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Race Against Time
Company management is currently in talks with creditors to secure extensions for the overdue financial reports. The next critical milestone for a fundamental reassessment of the business is set for June 2026. Gerresheimer plans to publish the audited annual statements by then, which, according to current impairment tests, will include non-cash writedowns of up to €240 million.
Ad
Gerresheimer Stock: New Analysis - 17 March
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
